Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a.

Abstract

S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon beta-1a in subjects with PPMS. The key questions were whether S100B levels were associated with either disability or MRI findings in primary progressive MS and whether Interferon beta-1a has an effect on their S100B levels. Serial serum S100B levels were measured using an ELISA method. The results demonstrated that serum S100B is not related to either disease progression or MRI findings in subjects with primary progressive MS given Interferon beta-1a. Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures.

• Authors: Ee Tuan Lim, Axel Petzold, Siobhan M Leary, Daniel R Altmann, Geoff Keir, Ed J Thompson, David H Miller, Alan J Thompson, Gavin Giovannoni
• Journal: Journal of negative results in biomedicine (J Negat Results Biomed) Vol. 3 Pg. 4 (Oct 13 2004) ISSN: 1477-5751 [Electronic] England
• PMID: 15482599 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Nerve Growth Factors
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins
• S100B protein, human
• Interferon-beta
• Interferon beta-1a

Topics

• Adult
• Case-Control Studies
• Female
• Humans
• Interferon beta-1a
• Interferon-beta (therapeutic use)
• Magnetic Resonance Imaging
• Male
• Multiple Sclerosis, Chronic Progressive (blood, drug therapy)
• Nerve Growth Factors (blood, metabolism)
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins (blood, metabolism)